💡NPCA Clinical Lead Alison Tree will present (unpublished) key findings from the upcoming State of the Nation Report and NPCA research updates at the British Uro-Oncology Group (BUG) Annual Meeting. 🗓️ Sept 13 @ 9.15 🔗 https://lnkd.in/ezVVeDZX Healthcare Quality Improvement Partnership (HQIP) National Cancer Audit Collaborating Centre (NATCAN)
National Prostate Cancer Audit (NPCA)
Hospitals and Health Care
The aim of the NPCA is to evaluate the patterns of care & outcomes for patients with prostate cancer in England & Wales.
About us
- Website
-
https://www.npca.org.uk/
External link for National Prostate Cancer Audit (NPCA)
- Industry
- Hospitals and Health Care
Updates
-
ICYMI Read the National Prostate Cancer Audit blog post for Clinical Audit Awareness Week #CAAW25 Healthcare Quality Improvement Partnership (HQIP) "The value of audit in identifying health inequalities" https://lnkd.in/eNM9U3MK Draws on NPCA State of the Nation report from January 2025 https://lnkd.in/erFwa-_k
-
⚠️ ICYMI Read the most recent NPCA publication https://lnkd.in/e8zRu3ui
📢 Start your week with the latest National Prostate Cancer Audit study. 👉 We found that the annual rate of metastatic prostate cancer at diagnosis was more than 60% higher in some regions than in others in England 👉 Regional annual rates were found to vary between 4 and 7 per 100 000 men, with the highest rates seen in Northern England; South Yorkshire and Bassetlaw; Humber, Coast and Vale; West Yorkshire and Harrogate; and the Peninsula. The lowest rates were seen in London and the South-East. 👉 Another key finding of this study is that higher rates of metastatic prostate cancer were seen in regions with lower rates of prostate cancer diagnosis overall which may be linked to variation in the use of PSA testing. 👉 A higher rate of metastatic prostate cancer and a lower rate of prostate cancer overall was also seen among men living in more deprived neighbourhoods, suggesting that the risk of being diagnosed with metastatic prostate cancer is also linked to their socioeconomic background. Full paper here https://lnkd.in/eFBy7-Mq National Cancer Audit Collaborating Centre (NATCAN) Healthcare Quality Improvement Partnership (HQIP) The Royal College of Surgeons of England The British Association of Urological Surgeons British Uro-oncology Group (BUG) NHS England Prostate Cancer UK British Urology Researchers in Training (BURST)
-
📢 Start your week with the latest National Prostate Cancer Audit study. 👉 We found that the annual rate of metastatic prostate cancer at diagnosis was more than 60% higher in some regions than in others in England 👉 Regional annual rates were found to vary between 4 and 7 per 100 000 men, with the highest rates seen in Northern England; South Yorkshire and Bassetlaw; Humber, Coast and Vale; West Yorkshire and Harrogate; and the Peninsula. The lowest rates were seen in London and the South-East. 👉 Another key finding of this study is that higher rates of metastatic prostate cancer were seen in regions with lower rates of prostate cancer diagnosis overall which may be linked to variation in the use of PSA testing. 👉 A higher rate of metastatic prostate cancer and a lower rate of prostate cancer overall was also seen among men living in more deprived neighbourhoods, suggesting that the risk of being diagnosed with metastatic prostate cancer is also linked to their socioeconomic background. Full paper here https://lnkd.in/eFBy7-Mq National Cancer Audit Collaborating Centre (NATCAN) Healthcare Quality Improvement Partnership (HQIP) The Royal College of Surgeons of England The British Association of Urological Surgeons British Uro-oncology Group (BUG) NHS England Prostate Cancer UK British Urology Researchers in Training (BURST)
-
The *first* National Prostate Cancer Audit Quarterly Data Dashboard is LIVE 📊 Cohort and indicator details can be found here https://lnkd.in/eF6yXa6D and the dashboard is accessible here rcs-ceu.shinyapps.io/NPCA/ The data quality metrics in this report (10.04.25) provide an overview of the quality of key data items for 158,607 people diagnosed with prostate cancer in England between 1st October 2021 and 30th September 2024. The performance indicator (emergency readmission within 90 days of radical prostate cancer surgery) in this report include 22,338 people who underwent radical prostate cancer surgery in England between 1st October 2021 – 31th June 2024. Please share these links and tell us what you think! 📝 npca@rcseng.ac.uk
-
National Prostate Cancer Audit (NPCA) reposted this
Professor and Consultant Clinical Oncologist. Clinical Director National Cancer Audits
NATCAN is one of largest national cancer quality assurance and improvement programs in the world. In our lancet oncology article below we profile the unique features of this audit program, how we differ from other programs internationally and future areas for development. Congrats to all the ten cancer audit teams who are working very hard to improve the quality of cancer care in the NHS with our many partners and stakeholders.
💥Read our Lancet Oncology paper 💥 https://buff.ly/YYBa1Aq “NATCAN provides an opportunity to use data science to inform clinical quality improvement across a range of cancers and reduce unwarranted variation in care.” NHS England The Royal College of Surgeons of England Healthcare Quality Improvement Partnership (HQIP) London School of Hygiene and Tropical Medicine, U. of London
-
-
🚨 6 days left to apply for the NPCA Clinical Fellow position! Advert is here https://lnkd.in/eY828z_b and please contact us npca@rcseng.ac.uk with any questions. Come and join the team 🙂
Do you want to help strengthen NHS cancer services & reduce variation in prostate cancer care? Are you a clinical oncological or urological trainee looking to pursue an MD or PhD with an expert clinical/audit team at the https://buff.ly/3F0dmcV If the answer to these questions is yes, look no further! The National Prostate Cancer Audit (NPCA) is recruiting a Clinical Fellow to work with our large and detailed outcome-linked dataset to undertake research for patient benefit. Apply here https://buff.ly/41yWxyv. More details about the NPCA can be found here https://buff.ly/4kiLhxy as well as our reports https://buff.ly/4klANxy and publications https://buff.ly/4kn1HF1. Enquiries can be made to npca@rcseng.ac.uk. Closing date 31st March 2025. Please share with your networks!
-
-
ICYMI last week, the NPCA's latest publication "Are evidence-based guidelines translating into clinical practice? A national population-based study of the use of treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC) in England" https://lnkd.in/enFGB29y
📢 End your week with our hot off the press paper: "Are Evidence-Based Guidelines Translating into Clinical Practice? A National Population-Based Study of the Use of Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in England" Available to read here https://lnkd.in/e95mUwpA The study explored variation in treatment intensification for mHSPC across England. Main findings include: 👉 Only 39% received intensification with lower uptake in Black and deprived populations 👉 Intensification was given to 60% of men under 75 but dropped to 17% in those over 75 👉 Use varied across sMDTs from 20% to 54%, with greater variation in older patients 👉 Findings highlight underuse and the need for standardised care to address disparities We hope you find this paper useful and please get in touch with any feedback npca@rcseng.ac.uk
-
-
📢 End your week with our hot off the press paper: "Are Evidence-Based Guidelines Translating into Clinical Practice? A National Population-Based Study of the Use of Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in England" Available to read here https://lnkd.in/e95mUwpA The study explored variation in treatment intensification for mHSPC across England. Main findings include: 👉 Only 39% received intensification with lower uptake in Black and deprived populations 👉 Intensification was given to 60% of men under 75 but dropped to 17% in those over 75 👉 Use varied across sMDTs from 20% to 54%, with greater variation in older patients 👉 Findings highlight underuse and the need for standardised care to address disparities We hope you find this paper useful and please get in touch with any feedback npca@rcseng.ac.uk
-
-
The audit's March 2025 Newsletter is OUT! Find out the latest news from the NPCA here https://lnkd.in/eaEuhTqv Please share it widely and email us npca@rcseng.ac.uk if you would like to receive it straight to your inbox.